# US 2020/0138743 A1 · Compositions comprising thymoquinone and omega-3 fatty acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138743 A1
- Document ID: US20200138743A1
- Status: Published application
- Kind: A1
- Application number: 16/631,037
- Filed: 2018-07-15
- Published: 2020-05-07
- Earliest claimed: 2017-07-15
- Assignees: Trinutra Ltd.
- Applicants: Trinutra Ltd.
- Inventors: Yoram SELA; Mor ZEILKHA; Itschak LAMENSDORF
- Web page: https://patentgrep.com/patent/US20200138743A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/404: Indoles, e.g. pindolol
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/71: Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition comprising a synergistic combination of thymoquinone and one or more omega-3 fatty acids, wherein the molar ratio between said thymoquinone and said one or more omega-3 fatty acids is at least 1:7. The present invention also provides a method of using said composition to treat or prevent inflammatory conditions.

## Claims

### Claim 1

A composition comprising a combination of TQ and one or more omega-3 fatty acids, wherein the molar ratio between said TQ and said one or more omega-3 fatty acids is at least 1:7.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the omega-3 fatty acids are in the form of free fatty acids, ethyl esters, or combinations thereof.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:200.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:150.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the molar ratio between TQ and the omega-3 fatty acids is in the range of 1:7-1:140.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the TQ is present in the composition in a form selected from the group consisting of intact BC seeds, ground BC seeds, BC seed oil, solvent extracts of BC seeds, supercritical CO2 extracts of BC oils, and/or partially purified extracts, purified extracts and/or fractions thereof.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the TQ is present in the composition in a form selected from the group consisting of intact oregano seeds, ground oregano seeds, oregano seed oil, solvent extracts of oregano seeds, supercritical CO2 extracts of oregano oils, and/or partially purified extracts, purified extracts and/or fractions thereof.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the TQ is synthetic TQ.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the one or more omega-3 fatty acids are selected from the group consisting of eicosapentaenoic acid (EPA), docosahexanoic (DHA) and alpha-iinoienic acid (ALA).

### Claim 10 (depends on 10)

The composition of claim 10, wherein the omega-3 fatty acids are highly concentrated oils containing a minimum of 50% w/w DHA & EPA in their free fatty acid or ethyl ester forms, and wherein the molar ratio between DHA and EPA is in the range of 1:1000 to 1000:1.

### Claim 11 (depends on 1)

The composition of claim 1, further comprising 3,3-diindolylmethane (DIM).

### Claim 12 (depends on 1)

A dosage form comprising the composition according to claim 1, wherein said dosage form is selected from the group consisting of a soft gelatin capsule, a sprinkle capsule, a sachet, a tablet, a syrup or other pharmaceutically acceptable oral dosage form.

### Claim 13 (depends on 12)

The dosage form according to claim 12, wherein the amount of TQ in said dosage form is 1-15% of the amount of omega-3 fatty acid.

### Claim 14 (depends on 12)

The dosage form according to claim 12, further comprising 3,3-diindolylmethane (DIM), wherein the amount of TQ in said dosage form is 1-15% of the amount of omega-3 fatty acid and the amount of DIM is 1-15% of the amount of omega-3 fatty acid.

### Claim 15 (depends on 1)

A method for the treatment, prevention, attenuation or inhibition of the progression of an inflammatory disease or a disease having an inflammatory component in a mammalian subject, comprising the administration of a composition according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, pelvic inflammatory disease, atherosclerosis, periodontitis, ulcerative colitis, Crohn's disease, psoriasis, multiple sclerosis, AMD, other possible eye inflammatory related diseases, inflammatory bowel disease and asthma.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the mammalian subject is a human.

### Claim 18 (depends on 1)

A composition according to claim 1 for use as a medicament.

### Claim 19 (depends on 1)

A composition according to claim 1 for use in the treatment, prevention, attenuation or inhibition of the progression of an inflammatory disease or a disease having an inflammatory component.
